Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 5, Issue 171, Pages 171ra17-171ra17
Publisher
American Association for the Advancement of Science (AAAS)
Online
2013-02-07
DOI
10.1126/scitranslmed.3004828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of the human TRAIL gene
- (2012) Joshua E. Allen et al. CANCER BIOLOGY & THERAPY
- Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
- (2012) J. E. Allen et al. MOLECULAR CANCER THERAPEUTICS
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
- (2011) Hiromichi Ebi et al. JOURNAL OF CLINICAL INVESTIGATION
- Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis
- (2011) Julien van Grevenynghe et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
- (2011) Theonie Anastassiadis et al. NATURE BIOTECHNOLOGY
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death
- (2010) Kageaki Kuribayashi et al. CANCER BIOLOGY & THERAPY
- Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer
- (2010) Jer-Yen Yang et al. CANCER RESEARCH
- A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- TRAIL receptor signaling and therapeutics
- (2010) Junaid Abdulghani et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- A Better TRAIL Variant for Tumor Cell-Specific Targeting? - Letter
- (2010) E. Bremer et al. MOLECULAR CANCER THERAPEUTICS
- Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells
- (2009) Soo-Jung Park et al. CELLULAR SIGNALLING
- Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
- (2009) C. H. Mom et al. CLINICAL CANCER RESEARCH
- Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
- (2009) Stephen Leong et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy
- (2009) Lata G. Menon et al. STEM CELLS
- Synthesis of New Pyrrolo[1,2-a]quinoxaline Derivatives as Potential Inhibitors of Akt Kinase
- (2008) Vanessa Desplat et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
- (2008) F. Anthony Greco et al. LUNG CANCER
- ERK and MDM2 prey on FOXO3a
- (2008) Wensheng Yang et al. NATURE CELL BIOLOGY
- ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
- (2008) Jer-Yen Yang et al. NATURE CELL BIOLOGY
- FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells
- (2008) A N Cornforth et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now